What We Do
1 – TID
Target Identification
- Identify and validate structural proteins
- Characterize target druggability through in silico and experimental data
2 – F2H
FIELDS TO HIT
- Match targets with FIELDS real data
3 – HV
HIT VALIDATION
- Validate binding pocket and property enumeration
4 – H2L
HIT TO LEAD
- Iterative screening, Med-Chem tractability, and lead identification
5 – LO
LEAD OPTIMIZATION
- NCEs to synthesis
- SAR to lead selection
6 – CN
Candidate Nomination
- ADME-Tox
- Efficacy
- Developability
- Pre-formulation
Precise: Our training set of real empirical/wet lab data allows us to cover the spectrum of protein/small molecule interactions to discover targetable hot spots, minimizing the “hit-and-miss” of traditional drug discovery.
Accelerated: Cutting-edge platform supported by decades of work and over 5 years of AI/ML development to discover new medicines with previously impossible speed and accuracy.
Validated: FIELDS™ is trained on hundreds of 3D structures, from PDB and DeepMind AlphaFold protein targets, screened against our IP rich proprietary fragment and NCE library.
Pipeline
ONCOLOGY
CDK9
Neuroendocrine Prostate
mCRPC
Other Solid Tumors
Leukemias
IPF (D0D Funded)
Q3 2023
Q4 2023
PIM1
Multiple Myeloma
Fibrotic Disorders
Q4 2023
Q1 2024
CNS
HDAC6
Neurodegenerative
Diseases – ALS/AD
Q1 2024
Q1 2025
SERVICES
PIPELINE PARTNERSHIPS
Biolexis utilizes the FIELDS™ platform to discover and develop our own NCEs. Our pipeline projects are available for licensing or partnering.
NCE DISCOVERY AND DEVELOPMENT
FIELDS™ can discover and develop innovative, IP-rich NCEs targeting any class of proteins. Our training set of real empirical/wet lab data allows us to cover the spectrum of protein/small molecule interactions and discover targetable hot spots on target proteins. FIELDS™ takes you from simple concept to drugable NCEs in a fraction of the time.
FIELDS™ CHALLENGE
Give us your most challenging protein target and we'll show you what FIELDS™ can do.